Genetics Institute of America

Name

Genetics Institute of America

Legal name

Genetics Institute of America

Website

https://genlabus.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Clinical Molecular Diagnostics Laboratory

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Medical and Diagnostic Laboratories (62151)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)

akta.pro secondary industries

Genetic & Prenatal Testing Laboratories (HLAFAMAH), Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Genomics & Molecular Diagnostics (Trial Support) (HLAGAEAD)

Keywords

• Molecular diagnostics laboratory
• Cancer genetic testing
• Pharmacogenetics testing
• Urine-based cancer diagnostics
• HRD biomarker testing

Headquarters

HQ city

Delray Beach

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. Clinical Laboratory Testing Services: CAP/CLIA accredited high-complexity molecular laboratory providing clinical genetic testing services to physicians and patients, including germline cancer panels, pharmacogenetics testing, and specialized diagnostic assays.
2. Pharma Services and Research: Contract research organization services including IRB-approved clinical studies, DNA/RNA/mRNA/miRNA studies on clinical specimens, and collaborative research with pharmaceutical companies.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels7 records

Core offering

Genetics Institute of America operates a CAP/CLIA/GLP-accredited high-complexity molecular diagnostics laboratory that performs clinical genetic testing and pharma research services. Its core commercial products are the GIAnomics™ family of germline cancer and pharmacogenetics panels, the GIAstat™ MPN Panel, the AI-enabled OncoPredikt HRD test, and the non-invasive urine-based PanGIA Prostate diagnostic, all delivered to physicians, patients, and pharmaceutical clients.

Product overview

Genetics Institute of America (GIA) offers a comprehensive genetic testing portfolio centered around its GIAnomics™ family of tests. The core offering includes germline cancer testing panels, pharmacogenetics panels, and a GIAstat MPN panel for hematologic disorders, with additional somatic and hematologic panels in development. The company also provides OncoPredikt HRD Testing for AI-enabled homologous recombination deficiency prediction. A key product is PanGIA Prostate, a non-invasive urine-based diagnostic platform that uses machine learning to analyze bio molecular signatures and help reduce unnecessary prostate biopsies. GIA conducts multiple IRB-approved clinical studies (GH101, GH215, GH216, GH217, GH218) exploring urine-based cancer detection across multiple cancer types. The company operates as a CAP/CLIA/GLP accredited laboratory offering clinical and research services to physicians, patients, and pharmaceutical companies.

Differentiator

Problem solved

Functional benefit

Brands

• GIAnomics™: A family of genomics tests including Oncology Germline, Pharmacogenetics, and other panels for clinical decision support.
• GIAstat™ MPN Panel
• OncoPredikt HRD Testing
• PanGIA Prostate

Products and services

• GIAnomics™ Oncology Germline Panel Germline cancer testing panel that supports clinical decision making for hereditary cancer risk assessment, designed for oncologists and other clinicians ordering hereditary cancer risk evaluation for their patients.
• GIAnomics™ Pharmacogenetics Panel Pharmacogenetics assays that assist in medication choice and initiation based on genetic factors affecting drug response, intended for clinicians managing patients with mental health conditions, chronic disease, and other drug-response considerations.
• GIAstat™ MPN Panel Myeloproliferative Neoplasm (MPN) diagnostic panel for hematologic testing, designed for hematologists and clinicians evaluating patients with suspected MPN.
• OncoPredikt HRD Testing AI-enabled prediction of Homologous Recombination Deficiency (HRD) to guide PARP inhibitor therapy decisions for cancer patients, designed for oncologists treating breast, ovarian, prostate, and pancreatic cancers.
• PanGIA Prostate Non-invasive urine-based prostate cancer diagnostic platform using AI and proprietary NuTec signatures to stratify patients and help reduce unnecessary biopsies, designed for urologists and primary care physicians evaluating patients with elevated PSA or prostate cancer risk.
• GH101 Clinical Study - Genetic Susceptibility to Chronic Disease IRB-approved clinical study using an integrative approach combining pharmacogenomics, cancer genomics, mRNA microarrays, and nutrigenomics to identify differentially expressed genes associated with chronic diseases including cardiovascular disease, end stage renal disease, PTSD, and cancers. Open to practices and research participants through study enrollment.
• GH215 Clinical Study - Urine Analysis for Prostate Cancer IRB-approved clinical study using urine analysis and the proprietary OpsisDx technology for prostate cancer diagnosis, with study enrollment available through participating practices.
• Genetic Counseling Service Genetic counseling services to help patients and providers understand genetic test results, review insurance coverage, and make informed healthcare decisions, delivered as part of the clinical testing workflow.
• GIAnomics™ At-Home Test Kit Patient-facing at-home test kit with buccal swab collection used for germline cancer and pharmacogenetics sample collection, ordered through giagenetics.com with physician authorization outreach by GIA.

Quantifiable outcome

• 97.8% sensitivity across all Gleason grades for urine-based prostate cancer detection (from related research)
• +2 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature5 records

Partnerships

Five partnerships are on record, tiered core and minor.

• Designer Genomics InternationalcoreStrategic or Co-development Partner · 12 March 2020Designer Genomics International, a Contract Research Organization (CRO), selected Genetics Institute of America as the IRB-approved testing laboratory for a clinical study into inflammasome activation. GIA runs DNA, RNA, mRNA and miRNA studies on buccal swab specimens. The collaboration leverages GIA's experience with DNA/RNA analysis and collaborative relationship with ThermoFisher Scientific for the GH101 Genetic Susceptibility to Chronic Disease study.
• 4KIDSminorOthers4KIDS is one of the leading foster care agencies in South Florida and the country, dedicated to bringing hope, homes, and healing to kids and families in crisis. GIA partners with 4KIDS through toy drives, sponsorship of events like Night of Impact, and ongoing support for foster families in South Florida.
• CROS MinistriesminorOthersCROS Ministries has been fighting against hunger in South Florida for 43 years, supporting 14 different types of food pantries serving Palm Beach and Martin Counties. GIA serves as presenting sponsor for the CROS Ministries Hustle to End Hunger 5K and supports their food pantry and community programs.
• The Lord's PlaceminorOthersThe Lord's Place is a social impact agency committed to ending the cycle of homelessness in South Florida. GIA has partnered with The Lord's Place to provide training and job opportunities for homeless individuals, embodying GIA's mission to create an inclusive corporate culture.
• Wheels from the Heart and Men TalkminorOthersGIA sponsors 'UNITY in the commUNITY' events organized by Wheels from the Heart and Men Talk. These events bring diverse communities together through dialogue about race relations and include car donations to families in need. CEO Holly Magliochetti participates as a panel speaker at annual events.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Myriad Genetics: Established leader in hereditary cancer genetic testing (BRACAnalysis, myRisk) and pharmacogenetics. Closely comparable product portfolio and physician channel, but with far greater scale and payor coverage than GIA.
• Natera: Molecular diagnostics company with oncology (Signatera ctDNA) and reproductive health genetics. Comparable in oncology liquid biopsy and hereditary cancer testing, with substantially larger commercial infrastructure.
• Invitae: Genetic testing company offering comprehensive hereditary cancer panels and pharmacogenomics — overlapping directly with GIAnomics™ germline and pharmacogenetic panels.
• NeoGenomics: Specialized oncology molecular diagnostics lab serving physicians and pharma with similar CAP/CLIA clinical and research service offerings across hematologic and solid tumor testing.
• Caris Life Sciences: Cancer molecular diagnostics and AI-driven profiling (MI Profile, Caris Assure). Comparable oncology molecular diagnostics and AI/ML capabilities with deeper pharma/biopharma services.
• Guardant Health: Liquid biopsy leader in oncology with Guardant360 and HRD/companion diagnostics. Directly comparable in non-invasive cancer detection and HRD prediction, but at much larger commercial scale.

Emerging players

• Personalis: Cancer genomics company focused on ImmunoID and tumor profiling with AI-driven analytics — overlapping with GIA's AI-enabled precision oncology approach but addressing different indications.

Broad incumbents

• Foundation Medicine: Roche-owned comprehensive genomic profiling for oncology. Operates broadly in cancer genomics as part of Roche's portfolio and competes with GIA's HRD and somatic testing directions.
• Exact Sciences: Cancer diagnostics leader with Cologuard and Oncotype products. Broad incumbent in cancer screening and diagnostics with far larger commercialization footprint than GIA.
• Quest Diagnostics: Major reference laboratory offering hereditary cancer panels, pharmacogenetics, and oncology diagnostics — overlapping product set with GIA's GIAnomics family as part of a much broader testing menu.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/geneticsamerica
• YouTubeyoutube.com/@geneticsinstituteofamerica
• Facebookfacebook.com/geneticsamerica
• LinkedInlinkedin.com/company/genetics-institute-of-america
• Instagraminstagram.com/geneticsamerica

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Genetics Institute of America